Just some quick notes:
1. The PH is NOT among the
invited countries in the proposed TPP Agreement. Of the 10 ASEAN countries, only 4 were invited by the US -- Singapore Malaysia, Brunei and Vietnam.
Notice also that these other Pacific countries were not invited: Indonesia, Taiwan, Ecuador, Colombia, Panama, Costa Rica, Nicaragua, El Salvador, Honduras, Guatemala. China and Hong Kong should have been deliberately not invited by the US because they are, well, China.
2. Other Asian countries like the PH have expressed
interest to join the TPP someday, but they are not priorities at the moment.
The priorities are to consolidate the final, common agreement among original
member-countries. There is no formal TPP Agreement yet.
3. A lot of the noise and opposition to TPP especially on IPR provisions seem to be based on "leaked documents". I myself seldom read the official documents, partly because my advocacy -- and that of our free market allies in Asia -- is unilateral trade liberalization, not so much those costly and time-consuming regional and multilateral trade negotiations, and the PH is not part of this proposed agreement.
4. Medyo madami pang
kakaining kanin ang Pinas, the PH need to mature more before
it can be admitted to the TPP. Like it
must amend its constitution to allow more foreign investments and competition into the country.
Under TPP, Jollibee, Chowking, SM, San Miguel, Metrobank, Mercury, Unilab, other Filipino
multinationals can easily invest in TPP member countries but those countries
cannot easily bring in their companies to the PH because of our
protectionist constitution.
5. Pharma IPR apply only to newly-invented medicines and
vaccines, not to old ones. If people are happy with existing, off-patent medicines and vaccines
because they are also disease-killers and are cheaper with many generics
equivalent, IPR is a non-issue. The fear of "IPR and expensive
medicines" apply only to a very small percentage of all medicines
available in the market. Another fear, "IPR and limited/non-access to cheap medicines of developing countries" is an urban legend. As stated above, IPR protection does not apply to old, off-patent medicines, and these products comprise the majority of medicines in the market. Up to 99 percent of the WHO's essential medicines list (EML), if my memory is correct.
See also:
IPR and Medicines 30: R&D and Innovator Companies, November 03, 2014
IPR and Medicines 31: Trademark Stealing and Counterfeit Medicines, November 17, 2014
IPR and Medicines 30: R&D and Innovator Companies, November 03, 2014
IPR and Medicines 31: Trademark Stealing and Counterfeit Medicines, November 17, 2014
IPR and Medicines 32: The Policy Workshop's Hong Kong Dialogue, November 28, 2015
No comments:
Post a Comment